The baseline Lp-PLA2 levels measured after the initial ACS event did not predict for the risk of recurrent cardiovascular events (death, myocardial infarction, unstable angina, revascularization, or stroke) at a follow-up from 18 to 36 months (mean 24 months). Here, PLA2G7 is linked to stroke disorder.